Home / Market News / $ILMN

$ILMN news and market catalysts

The 35 most recent market catalysts affecting $ILMN, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

35 catalysts 2 high impact 29 bullish 4 bearish Biotechnology
Nov 9, 2026 Corporate Catalyst Bullish Impact 60
Illumina Expands Molecular Residual Disease (MRD) Research Portfolio
Illumina has launched an early access program for its new ultrasensitive duplex sequencing technology, specifically targeting molecular residual disease (MRD) research. This is a p…
Nov 5, 2026 Corporate Catalyst Bearish Impact 65
Resumption of Illumina Royalty Payment Announced
The filing indicates that Illumina will begin receiving royalty payments again in late December 2026, which is projected to positively impact its gross margins from the first quart…
Nov 3, 2026 Corporate Catalyst Bullish Impact 55
Illumina Selected to Support Precision Medicine in Singapore
Illumina announced its selection to participate in Singapore's precision medicine efforts, aiming to integrate genomic analysis into routine clinical practice. This is significant …
Nov 2, 2026 Corporate Catalyst Bullish Impact 55
Citigroup Maintains Illumina at Sell and Raises Price Target
Citigroup analyst Patrick B. Donnelly has maintained a 'Sell' rating on Illumina (ILMN), which is a significant signal of continued bearish sentiment from the firm. While the price…
Oct 30, 2026 Corporate Catalyst Bullish Impact 55
Evercore ISI Group Maintains Illumina at Outperform, Lowers Price Target
Evercore ISI Group, a prominent analyst firm, maintained its 'Outperform' rating on Illumina but reduced its price target by $15, or 5.2%. This action signals a slightly diminished…
Oct 30, 2026 Corporate Catalyst Bearish Impact 55
JPMorgan Adjusts Price Target on Illumina to $300 From $320
JPMorgan, a major financial institution, has adjusted its price target for Illumina (ILMN) downwards from $320 to $300. This change, reported on October 30, 2026, signifies a revis…
Oct 29, 2026 Corporate Catalyst Bullish Impact 75
Illumina Reports Third Quarter 2026 Financial Results and Raises Full-Year Guidance
Illumina announced robust third-quarter 2026 financial results, exceeding expectations with a 4.2% revenue increase year-over-year. This strong performance, attributed to high clin…
Oct 23, 2026 Corporate Catalyst Bearish Impact 65
Stephens Downgrades Illumina to Equal Weight
Investment firm Stephens has downgraded Illumina (ILMN) from Overweight to Equal Weight, establishing a price target of $275. This action signals a more cautious stance from Stephe…
Oct 19, 2026 Corporate Catalyst Bullish Impact 55
Canaccord Genuity Maintains Hold on Illumina, Raises Price Target to $300
Canaccord Genuity analyst Kyle Mikson raised the price target for Illumina (ILMN) from $205 to $300, while maintaining a 'Hold' rating. This substantial increase in the price targe…
Oct 13, 2026 Corporate Catalyst Bullish Impact 55
TD Cowen Maintains Hold on Illumina, Raises Price Target to $270
TD Cowen analyst Dan Brennan raised the price target for Illumina (ILMN) from $210 to $270, while keeping a 'Hold' rating. This action reflects an updated valuation model or improv…
Oct 7, 2026 Corporate Catalyst Bullish Impact 55
Barclays Maintains Underweight on Illumina, Raises Price Target to $200
Barclays analyst Luke Sergott maintained an 'Underweight' rating on Illumina but raised the price target from $160 to $200. This indicates a nuanced view: while the analyst still s…
Oct 5, 2026 Corporate Catalyst Neutral Impact 75
GRAIL To Present New NHS-Galleri Trial Data At Early Detection Of Cancer Conference And ESMO Congress
The upcoming presentation of NHS-Galleri trial data is a significant corporate catalyst for Illumina (ILMN) due to its ownership of GRAIL. Positive data could validate GRAIL's mult…
Oct 5, 2026 Corporate Catalyst Bullish Impact 75
Illumina shares are trading higher after RBC Capital raised its price target on the stock from $230 to $310.
This headline represents a significant corporate catalyst for Illumina. An analyst upgrade from a reputable firm like RBC Capital, coupled with a substantial price target increase,…
Oct 5, 2026 Corporate Catalyst Bullish Impact 55
RBC Capital Maintains Outperform on Illumina, Raises Price Target to $310
RBC Capital analyst Dan Leonard maintained an 'Outperform' rating on Illumina (ILMN) and raised the price target from $230 to $310. This action signals increased confidence from a …
Oct 1, 2026 Corporate Catalyst Bullish Impact 55
Guggenheim Maintains Buy on Illumina, Raises Price Target to $305
Guggenheim's analyst Subbu Nambi maintaining a 'Buy' rating and significantly raising the price target for Illumina (ILMN) from $226 to $305 indicates a strong belief in the compan…
Sep 29, 2026 Corporate Catalyst Bullish Impact 65
Leerink Partners Maintains Outperform on Illumina, Raises Price Target to $300
Leerink Partners analyst Puneet Souda maintained an 'Outperform' rating on Illumina and raised the price target from $220 to $300. This is a significant upgrade, indicating increas…
Sep 28, 2026 Corporate Catalyst Bullish Impact 55
Piper Sandler Maintains Overweight on Illumina, Raises Price Target to $305
Piper Sandler analyst David Westenberg has maintained an 'Overweight' rating on Illumina (ILMN) and raised the price target from $225 to $305. This action signals increased confide…
Sep 23, 2026 Corporate Catalyst Bullish Impact 85
U.S. FDA Advisers Back Safety Of GRAIL's Galleri Multi-Cancer Screening Test; FDA Advisers Vote 6-4 That GRAIL's Galleri Is Effective For Proposed Use In Multi-Cancer Screening Test; Advisers Vote 7-2, With One Abstention, That Benefits Of GRAIL's Galleri Test Outweigh Risks For Proposed Use
FDA advisers have given a strong endorsement to GRAIL's Galleri multi-cancer screening test, voting favorably on both its safety and efficacy for its proposed use. This is a critic…
Sep 21, 2026 Corporate Catalyst Neutral Impact 75
The FDA Posted Briefing Documents For Grails Galleri Test Review Ahead Of The Molecular And Clinical Genetics Panel Of The Medical Devices Advisory Committee That Is Being Held On September 23; Flags No Major Concerns For Co's Cancer Test
The FDA's posting of briefing documents for GRAIL's Galleri test review, specifically noting 'no major concerns,' is a significant development. This suggests a smoother path toward…
Sep 9, 2026 Corporate Catalyst Bullish Impact 65
This Illumina Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday
The filing details several analyst upgrades, with the most significant being UBS's upgrade of Illumina (ILMN) from Neutral to Buy and a substantial price target increase from $135 …
Sep 9, 2026 Corporate Catalyst Bullish Impact 75
UBS Upgrades Illumina to Buy, Raises Price Target to $260
UBS analyst Doug Schenkel upgraded Illumina (ILMN) from Neutral to Buy and raised the price target from $135 to $260. This significant upgrade from a major investment bank indicate…
Sep 3, 2026 Corporate Catalyst Bullish Impact 55
Argus Research Maintains Buy on Illumina, Raises Price Target to $235
Argus Research analyst Jasper Hellweg maintained a 'Buy' rating on Illumina and significantly raised the price target from $180 to $235. This action indicates a stronger conviction…
Aug 3, 2026 Corporate Catalyst Bullish Impact 55
Citigroup Maintains Sell on Illumina, Raises Price Target to $113
This filing discloses that Citigroup's analyst Joanne Wuensch has maintained a 'Sell' rating on Illumina (ILMN), but has also raised the price target from $95 to $113. This action …
Aug 3, 2026 Corporate Catalyst Bullish Impact 55
Piper Sandler Reiterates Overweight on Illumina, Raises Price Target to $225
Piper Sandler analyst David Westenberg has reiterated an 'Overweight' rating on Illumina (ILMN) and raised the price target from $200 to $225. This action signals continued confide…
Jul 31, 2026 Corporate Catalyst Bullish Impact 55
RBC Capital Maintains Outperform on Illumina, Raises Price Target to $230
RBC Capital's analyst Dan Leonard has maintained an 'Outperform' rating on Illumina and raised the price target from $170 to $230. This upward revision in the price target, a subst…
Jul 31, 2026 Corporate Catalyst Bullish Impact 55
JP Morgan Maintains Overweight on Illumina, Raises Price Target to $230
JP Morgan analyst Casey Woodring has maintained an 'Overweight' rating on Illumina and raised the price target from $220 to $230. This action signals continued confidence in Illumi…
Jul 31, 2026 Corporate Catalyst Bullish Impact 55
TD Cowen Maintains Hold on Illumina, Raises Price Target to $210
TD Cowen analyst Dan Brennan raised the price target for Illumina (ILMN) from $192 to $210, while keeping a 'Hold' rating. This adjustment suggests a slightly improved valuation ou…
Jul 31, 2026 Corporate Catalyst Bearish Impact 75
Illumina shares are trading lower after the company reported its Q2 financial results. The stock initially rallied yesterday after the market closed, but it has since reversed.
The headline points to a corporate catalyst – Illumina's Q2 financial results – as the primary driver of its stock movement. The initial rally followed by a reversal suggests that …
Jul 31, 2026 Corporate Catalyst Bullish Impact 55
Guggenheim Maintains Buy on Illumina, Raises Price Target to $226
Guggenheim analyst Subbu Nambi maintained a 'Buy' rating on Illumina (ILMN) and raised the price target from $200 to $226. This action signals a strengthened positive outlook from …
Jul 31, 2026 Corporate Catalyst Bullish Impact 55
Stifel Maintains Buy on Illumina, Raises Price Target to $225
This filing indicates that Stifel, through its analyst Daniel Arias, has reaffirmed its 'Buy' rating for Illumina (ILMN) and substantially raised its price target from $155 to $225…
Jul 31, 2026 Corporate Catalyst Bullish Impact 55
Barclays Maintains Underweight on Illumina, Raises Price Target to $160
This filing discloses that Barclays analyst Luke Sergott has maintained an 'Underweight' rating on Illumina (ILMN) while simultaneously raising the price target from $145 to $160. …
Jul 30, 2026 Corporate Catalyst Bullish Impact 92
Illumina shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 guidance above estimates.
Illumina's better-than-expected Q2 results and significantly raised FY26 guidance are a major positive catalyst for the company. This indicates strong underlying business fundament…
Jul 30, 2026 Corporate Catalyst Bullish Impact 75
Illumina Q2 Adj. EPS $1.31 Beats $1.23 Estimate, Sales $1.159B Beat $1.130B Estimate
This headline represents a significant positive corporate catalyst for Illumina. Beating both EPS and revenue estimates indicates robust underlying business performance, likely dri…
Jul 17, 2026 Corporate Catalyst Bullish Impact 60
Leerink Partners Maintains Outperform on Illumina, Raises Price Target to $210
Leerink Partners analyst Puneet Souda has maintained an 'Outperform' rating on Illumina (ILMN) and raised the price target from $175 to $210. This action signals increased confiden…
Jul 14, 2026 Corporate Catalyst Bullish Impact 55
Canaccord Genuity Maintains Hold on Illumina, Raises Price Target to $190
Canaccord Genuity analyst Kyle Mikson has raised the price target for Illumina (ILMN) from $140 to $190, while simultaneously maintaining a 'Hold' rating. This indicates that while…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.